# Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer

> **NCT03373708** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Zhiyong Yu** · enrollment: 200 (estimated)

## Conditions studied

- Breast Cancer
- Chemotherapy
- Endocrine Breast Diseases

## Interventions

- **DRUG:** Epirubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** Docetaxel
- **DRUG:** Goserelin acetate
- **DRUG:** Tamoxifen
- **DRUG:** Letrozole

## Key facts

- **NCT ID:** NCT03373708
- **Lead sponsor:** Zhiyong Yu
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-12-20
- **Primary completion:** 2019-12-20
- **Final completion:** 2019-12-20
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2017-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03373708

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03373708, "Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03373708. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*